Candel Therapeutics

Candel Therapeutics, Inc. operates as a biopharmaceutical company that develops and commercializes cancer immunotherapy drugs. It offers aglatimagene besadenovec (CAN-2409), a replication-deficient adenovirus that delivers within infected cancer cells the herpes simplex virus thymidine kinase (HSV-tk) gene. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc (NASDAQ:CADL) CEO Paul Peter Tak expressed optimism for a "paradigm shift" in prostate cancer treatment as the biopharmaceutical company moves closer to phase 2b and phase 3 trial data releases for its lead therapy, CAN-2409. Tak stated the data, expected in the fourth quarter of 2024, could pave the way for new regulatory approvals for CAN-2409 in non-metastatic, localized prostate cancer.

Candel Therapeutics CEO anticipates 'paradigm shift' in prostate cancer treatment as Q3 work wraps up

Candel Therapeutics Inc (NASDAQ:CADL) recently presented insights into its oncolytic virus therapy, CAN-3110, at the Society for Immunotherapy of Cancer (SITC) conference. The company's Chief Scientific Officer, Dr.

Candel Therapeutics' CAN-3110 offers new hope for melanoma treatment – ICYMI

Candel Therapeutics Inc (NASDAQ:CADL) announced that preclinical data from its CAN-3110 program indicate promising antitumor activity in melanoma, suggesting a potential expansion beyond the candidate's original focus on recurrent high-grade glioma. The findings, to be presented at the Society for Immunotherapy of Cancer (SITC) annual meeting, highlight CAN-3110's dual mechanisms of oncolysis and immune activation in melanoma models.

Candel Therapeutics eyes new indication for CAN-3110 in melanoma following positive preclinical results

NEEDHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced preclinical results and therapeutic potential of CAN-3110 in the Ras-Raf pathway altered melanoma model. The data will be presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 6-10, in Houston, Texas by Anne R. Diers, PhD, Senior Director of Research at Candel Therapeutics.

Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma

Candel Therapeutics is working on intratumoral oncolytic virus therapy. A pair of mid to late-stage trials in prostate cancer are expected to read out in Q4. Positive findings could be the position of strength the company needs to raise funds, which are in dire straits.

Candel Therapeutics: A Low-Price Oncolytic Virus Plays Further Along Than You Think

NEEDHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present a poster at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting taking place November 6-10, 2024 in Houston, Texas and virtually.

Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting

Rocket Pharma

Viridian Therapeutics

The huge sector rotation we have seen in the market over the past few weeks has significantly benefited the SPDR® S&P Biotech ETF. If this trend continues, small-cap names within the sector should continue to advance. Today, we look in more detail at three small/mid-cap biotech stocks with potential catalysts that should hit before the end of 2024.

3 Biotech Names With Potential Catalysts By Year End

NEEDHAM, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the Company is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.

Candel Therapeutics to Join Russell 3000® Index

NEEDHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-3110, a next generation oncolytic viral immunotherapy, for the treatment of recurrent high-grade glioma (rHGG). Glioblastoma (GBM) is the most common and aggressive form of high-grade glioma.

FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma

Candel (CADL) surges 431% in the year-to-date period, driven by positive developmental and regulatory updates from the clinical program for CAN-2409 across two different cancer indications.

Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why

Candel's (CADL) CAN-2409 prolongs overall survival in a phase II study for treating patients with advanced non-small cell lung cancer who are non-responsive to immune checkpoint inhibitor therapy.

Candel (CADL) Reports Upbeat Data From Lung Cancer Study

NEEDHAM, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced topline overall survival data from its phase 2 clinical trial of CAN-2409, a multimodal biological immunotherapy candidate, plus valacyclovir (prodrug), together with standard of care (SoC) immune checkpoint inhibitor (ICI) therapy in patients with Stage III/IV non-small cell lung cancer (NSCLC) inadequately responding to ICI (anti-PD-(L)1) therapy.  The data will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago, May 31 to June 4, 2024, by Charu Aggarwal, MD, MPH, FASCO, Leslye M. Heisler Associate Professor for Lung Cancer Excellence at the Perelman School of Medicine, University of Pennsylvania and Co-Principal Investigator of the clinical trial.

Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting

NEEDHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, Candel's President and Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 5:30 p.m. ET.

Candel Therapeutics to Present at the Jefferies Global Healthcare Conference

Management and scientific/medical thought leaders to discuss topline overall survival data from phase 2 clinical trial of CAN-2409 in NSCLC Management and scientific/medical thought leaders to discuss topline overall survival data from phase 2 clinical trial of CAN-2409 in NSCLC

Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting

NEEDHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

NEEDHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that two abstracts were accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 to June 4, 2024, in Chicago, IL. The first presentation will feature data from the ongoing phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma. The presentation will focus on patients recruited in cohort C, treated with multiple injections of CAN-3110 (up to six), demonstrating that this approach is both feasible and well tolerated. The second presentation will show topline overall survival data from the phase 2 clinical trial of CAN-2409 plus valacyclovir, in combination with continued immune checkpoint inhibitor (ICI) treatment in patients with non-resectable, stage III/IV non-small cell lung cancer (NSCLC) who have an inadequate response to front line anti-PD(L)1 therapy.

Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

Candel Therapeutics, Inc. released positive interim results from the phase 2 study using CAN-2409 for treatment of patients with pancreatic ductal adenocarcinoma; Patients that took the drug with SOC achieved mOS of 28.8 months. Orphan Drug Designation is given by FDA for CAN-2409 for the treatment of patients with borderline respectable pancreatic ductal adenocarcinoma. Results from phase 2 study using CAN-2409 for the treatment of patients with non-small cell lung cancer, expected Q2 of 2024.

Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer

Candel (CADL) rallies 43% as the FDA grants the orphan drug designation to its lead candidate, CAN-2409, for treating non-metastatic pancreatic cancer.

Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag

NEEDHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-2409, Candel's most advanced multimodal biological immunotherapy candidate, for the treatment of pancreatic cancer.

Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer

NEEDHAM, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the presentation of a poster during the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5 through 10 in San Diego, which focused on a first-in-class multimodal immunotherapy candidate for induction of tertiary lymphoid structures (TLS), being developed as a novel therapeutic strategy for solid tumors from Candel's enLIGHTEN™ Discovery Platform.

Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors

Candel's (CADL) CAN-2409 demonstrates improvements in estimated median overall survival versus the control group in treating borderline resectable pancreatic ductal adenorcarcinoma. The stock rises.

Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study

Shares of Candel Therapeutics Inc. CADL, +280.95% climbed 15% early Friday after the company released new data from a trial of its experimental cancer treatment.

Candel Therapeutics stock jumps as pancreatic cancer treatment shows promise

Candel Therapeutics Inc is up roughly 30% in premarket on Friday after reporting positive interim data for its experimental treatment of non-metastatic pancreatic cancer. CAN-2409 data sends Candel Therapeutics stock up Patients on CAN-2409 showed a meaningful increase in survival in a Phase II study, as per the biotechnology company.

Candel Therapeutics stock soars 30%: find out more

MSP Recovery Inc

Perma-Fix Environmental Services

Palantir Technologies

If investing were easy, everybody would do it, and we would all be rich. But that isn't the case.

Unusually High Volume Points to Upside in These Stocks

NEEDHAM, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced updated interim survival data from the ongoing randomized phase 2 clinical trial of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection for borderline resectable pancreatic ductal adenocarcinoma (PDAC). Survival data were updated with eight months of further follow-up since the first analysis presented at the 2023 Society for Immunotherapy (SITC) Annual Meeting. Based on the data presented at SITC, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to the Company for CAN-2409 in combination with valacyclovir for the treatment of patients with PDAC in December 2023.

News for Candel Therapeutics Stock (CADL)